Education
About Us
Working with TipRanks
Follow Us
HeraMED Ltd. (AU:HMD)
ASX:HMD
HMD Stock Chart & Stats
AU$0.04
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.04
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.05
Previous CloseN/A
Volume370.09K
Average Volume (3M)1.96M
Market Cap
AU$44.55M
Enterprise ValueAU$21.62M
Total Cash (Recent Filing)AU$914.65K
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,113,653,400
10 Day Avg. Volume1,195,844
30 Day Avg. Volume1,958,766
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)41.38
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross MarginA sustained rise to ~60% gross margin indicates materially improved unit economics for HeraMED’s core device/software mix. If maintained, high gross margins provide room to absorb R&D and SG&A, enabling the business to scale toward profitability as revenue stabilizes and fixed costs leverage.
Deleveraged Balance SheetZero reported debt reduces financial risk and interest burden, giving management flexibility on capital allocation and fewer covenant constraints. This lower leverage profile improves resilience to revenue volatility and lengthens runway, easing the near-term funding pressure for strategic initiatives.
Aligned With Digital Women’s Health TrendHeraMED’s focus on software-enabled remote monitoring in women’s health matches structural healthcare trends toward telehealth and chronic-care management. Scalable SaaS and connected-device models can generate recurring revenue and high incremental margins if clinical adoption and payer pathways expand.
Bears Say
Persistent Cash BurnConsistently negative operating and free cash flow forces reliance on external funding, raising dilution or financing risk. Ongoing cash burn constrains investment in commercialization, talent, and regulatory work, and increases vulnerability if capital markets tighten or fundraising terms worsen.
Volatile And Declining RevenueRecent revenue contraction and historical volatility undermine operating leverage and make forecasting difficult. Without stable top-line growth, high gross margins may not translate into profit; weak revenue trends also signal potential demand, execution, or market-penetration challenges.
Shrinking Equity CushionA reduced equity base limits the company’s financial buffer against continued losses and reduces flexibility to absorb shocks. Negative returns on equity reflect persistent losses, which heighten refinancing risk and could force dilutive capital raises that impede long-term shareholder value.
HeraMED Ltd. News
HMD FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest share price was <AU$0.01 and its highest was AU$0.05 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is AU$44.55M.
When is HeraMED Ltd.’s upcoming earnings report date?
HeraMED Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 173 days.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is HeraMED Ltd. overvalued?
According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,113,653,400 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in AU:HMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeraMED Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-513.22%
Trailing 12-Months
Asset Growth
-54.47%
Trailing 12-Months
Company Description
HeraMED Ltd.
HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate monitor use by an expectant mother to monitor their fetus' heartbeat; and HeraCARE, a digital pregnancy monitor platform for the creation and implementation of digital health solutions for maternity care management. It also develops EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform. HeraMED Limited was incorporated in 2011 and is headquartered in Netanya, Israel.